Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRHR1 | P34998 | 1/20 | 0.66 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.66 |
| ▸ | CALCR | P30988 | 3/20 | 0.65 |
| ▸ | GLP1R | P43220 | 14/20 | 0.64 |
| ▸ | SCTR | P47872 | 1/20 | 0.62 |
| ▸ | CCKBR | P32239 | 1/20 | 0.61 |
| ▸ | GCGR | P47871 | 2/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29692863 | 0.94 | GLP1R (0.69) | GLP1RSCTRGCGR | |
| SCHEMBL30184797 | 0.94 | GLP1R (0.69) | GLP1RSCTRGCGR | |
| SCHEMBL29692881 | 0.94 | GLP1R (0.69) | GLP1RSCTRGCGR | |
| SCHEMBL30076320 | 0.94 | GLP1R (0.69) | GLP1RSCTRGCGR | |
| SCHEMBL29356509 | 0.94 | GLP1R (0.69) | GLP1RSCTRGCGR | |
| SCHEMBL29692888 | 0.94 | GLP1R (0.69) | GLP1RSCTRGCGR | |
| SCHEMBL29692871 | 0.94 | GLP1R (0.69) | GLP1RSCTRGCGR | |
| SCHEMBL31291000 | 0.94 | GLP1R (0.69) | GLP1RSCTRGCGR | |
| SCHEMBL30053976 | 0.94 | GLP1R (0.69) | GLP1RSCTRGCGR | |
| SCHEMBL30148474 | 0.94 | GLP1R (0.67) | CALCRGLP1RSCTRGCGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12358980-B2 | Compositions and methods for anti-PACAP antibodies | CEPHALON LLC (US) | 2025-07-15 | — | — | US | disclosed |
| US-20240374689-A1 | HIGHLY ACTIVE POLYPEPTIDES AND METHODS OF MAKING AND USING THE SAME | LONGEVITY BIOTECH, INC. | 2024-11-14 | — | — | US | disclosed |
| CN-118556079-A | Compositions and methods of anti-PACAP antibodies | 瑟法隆有限责任公司 | 2024-08-27 | — | — | CN | disclosed |
| US-20230212281-A1 | COMPOSITIONS AND METHODS FOR ANTI-PACAP ANTIBODIES | CEPHALON LLC | 2023-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240374689-A1 | HIGHLY ACTIVE POLYPEPTIDES AND METHODS OF MAKING AND USING THE SAME | SCTR, GIPR, APLNR | CRHR1 195/4885CRHR2 386/4885CALCR 118/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.